European Medicines Agency has been notified about the withdrawal of application for a marketing authorization for ridaforolimus for the maintenance treatment of patients with metastatic soft tissue sarcoma or bone sarcoma previously treated with chemotherapy. Read more here.
No comments:
Post a Comment